Tempus and NYU School of Medicine Announce New Initiative to Help Improve Outcomes for Pancreatic Cancer Patients

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, today announced... Read More
January 19, 2018

Luna DNA Announces Dawn Barry, former Illumina VP, as President

Luna DNA, the first and only genomic and medical research knowledge base powered by the blockchain and owned by its community, announced today Dawn... Read More
January 19, 2018

Clinical Genomics appoints Tadd Lazarus, MD, as Chief Medical Officer

Clinical Genomics, a leading provider of cancer diagnostic solutions and liquid biopsy tests, today announced the appointment of Tadd Lazarus, M.D., as Chief Medical... Read More
January 11, 2018

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has entered into a strategic, long-term partnership with GE Healthcare in order to jointly develop... Read More
January 10, 2018

Oncologists Can Now Specify Cancer Treatment Options to Score and Rank with CureMatch

CureMatch® will present the new release of PreciGENE™ Personalized Combination Therapy® at Biotech Showcase™ 2018, to be held January 8–10 in San Francisco. Oncologists... Read More
January 10, 2018

Renowned Scientists Join Rady Children’s Institute for Genomic Medicine Scientific Advisory Board

The Rady Children’s Institute for Genomic Medicine (RCIGM) is pleased to announce that six influential life science researchers have been recruited to serve on... Read More
January 10, 2018

Patients Can Now Request a OneOme RightMed® Test Through an Independent Provider Network

Precision medicine company OneOme is partnering with PWNHealth to increase patient access to the RightMed® comprehensive test without compromising patient safety. Until now, patients... Read More
January 10, 2018

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology

Syapse, a leading precision medicine company, announced today it has entered into a multi-year strategic collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) to... Read More
January 10, 2018

Concert Genetics Completes Growth Financing

Concert Genetics, Inc., has announced it has completed a growth capital financing round with a structured facility led by Deerfield Management. The funds will... Read More
December 15, 2017

Statement from FDA Commissioner Scott Gottlieb, M.D., on new FDA efforts to support more efficient development of targeted therapies

In recent years, the medical community has experienced a shift in the way health care is practiced. Rather than focusing solely on how to... Read More
December 13, 2017

RowAnalytics, Martinos Center & Envision Genomics Create GIRO Health, a new Flagship Open Initiative in Precision Medicine

RowAnalytics Ltd., the Martinos Center for Biomedical Imaging (Martinos Center) and Envision Genomics Inc. today announced that they are combining their world leading technologies... Read More
December 12, 2017

University of Cincinnati Cancer Institute Joins Caris Life Sciences’ Precision Oncology Alliance

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that the University of Cincinnati... Read More
December 12, 2017

Dr. Aradhana Ghosh Joins Precision Medicine Leader Syapse As Vice President of Oncology

Syapse, a market leader in precision medicine solutions, announced today that Dr. Aradhana Ghosh has joined the company as Vice President of Oncology. An... Read More
December 12, 2017

Personalized Cancer Medicine Research Spearheaded by CureMatch Co-Founders

CureMatch Co-Founders Igor F. Tsigelny, Ph.D. and Razelle Kurzrock, M.D. along with colleagues from UC San Diego and University of Bergen have authored a... Read More
December 12, 2017

Closing in on advanced prostate cancer

Xavier Salvatella, ICREA researcher at IRB Barcelona, ​​proposes a new approach to combat prostate tumour cells that have become unresponsive to the treatments currently... Read More
December 12, 2017

GNS Healthcare Uses Causal AI to Discover Which Multiple Myeloma Patients Will Have Progression Free Survival Benefit from Stem Cell Treatments

GNS Healthcare (GNS), a leading precision medicine company, together with the Multiple Myeloma Research Foundation (MMRF), have discovered a biomarker that identifies which multiple... Read More